RadioBDC Logo
My Silver Lining | First Aid Kit Listen Live
THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Cubist to buy drug firm Adolor

Total price could reach $415m Deal adds treatment in late-stage trials

By Robert Weisman
Globe Staff / October 25, 2011

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Cubist Pharmaceuticals Inc., a Lexington biotechnology company that has built its acute care franchise on antibiotics, yesterday said it has struck a deal to buy Pennsylvania drug maker Adolor Corp. for as much as $415 million in cash and stock. The deal, the largest in Cubist’s 19-year history, would give it an approved drug that helps patients recover from bowel resection surgery they undergo to treat conditions ranging from Crohn’s disease to colon cancer.

For more from BostonGlobe.com, sign up or log in below

To continue, please sign up or log in to BostonGlobe.com

Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com

Sign up

Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.

Are you a Boston Globe home delivery subscriber?

Get FREE access as part of your print subscription.

BostonGlobe.com subscriber

Click to continue reading this article or to log in to BostonGlobe.com.